Published in J Adolesc Health on October 01, 2008
Preventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical Cancers. Iran J Basic Med Sci (2012) 0.89
Using Facebook™ to Recruit College-Age Men for a Human Papillomavirus Vaccine Trial. Am J Mens Health (2014) 0.85
Modeling and molecular dynamics of the intrinsically disordered e7 proteins from high- and low-risk types of human papillomavirus. J Mol Model (2013) 0.81
A comparative analysis of gene expression patterns and cell phenotypes between cervical and peripheral blood mononuclear cells. PLoS One (2009) 0.79
Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice. Med Microbiol Immunol (2014) 0.78
Kudos to the virus hunters. Libyan J Med (2009) 0.75
Suppressive Effect of Constructed shRNAs against Apollon Induces Apoptosis and Growth Inhibition in the HeLa Cell Line. Iran Biomed J (2016) 0.75
Cervical Cancer Screening Among Arab Women in the United States: An Integrative Review. Oncol Nurs Forum (2017) 0.75
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Innate immune recognition. Annu Rev Immunol (2001) 26.65
Toll-like receptors. Annu Rev Immunol (2001) 26.06
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 20.60
Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol (2001) 18.80
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med (2007) 15.40
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature (1985) 11.11
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer (2007) 10.29
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Chapter 2: The burden of HPV-related cancers. Vaccine (2006) 7.70
Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J (1989) 7.69
Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet (2001) 7.31
Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol (2005) 5.97
Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. Adv Data (2005) 5.62
The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours. J Gen Virol (1985) 4.82
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA (2007) 4.66
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med (1997) 4.00
Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol (2003) 3.97
Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine (2006) 3.72
Human papillomavirus infection requires cell surface heparan sulfate. J Virol (2001) 3.32
Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA (2001) 3.07
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine (2007) 2.64
Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis (2005) 2.51
Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst (2005) 2.47
Immune responses to human papillomavirus. Vaccine (2006) 2.37
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology (2005) 2.31
Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A (1996) 2.06
Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics (2005) 1.94
Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol (2003) 1.82
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J (2007) 1.77
TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol (2007) 1.70
Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol (2003) 1.68
Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health (2007) 1.63
Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol (2001) 1.61
New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer (2002) 1.60
Induction of human papillomavirus type 18 late gene expression and genomic amplification in organotypic cultures from transfected DNA templates. J Virol (1997) 1.59
Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer (1986) 1.58
Characterization of events during the late stages of HPV16 infection in vivo using high-affinity synthetic Fabs to E4. Virology (1997) 1.56
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A (2007) 1.53
The dual immunoregulatory roles of stress proteins. Trends Biochem Sci (2008) 1.51
Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis (2000) 1.50
DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection. Eur J Immunol (2007) 1.50
Covariates of cervical cytokine mRNA expression by real-time PCR in adolescents and young women: effects of Chlamydia trachomatis infection, hormonal contraception, and smoking. J Clin Immunol (2006) 1.48
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis (2003) 1.40
Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol (2004) 1.40
Plane warts under spontaneous regression. Immunopathologic study on cellular constituents leading to the inflammatory reaction. Arch Dermatol (1986) 1.39
DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther (2007) 1.37
A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res (2000) 1.32
CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer (2007) 1.31
Papillomavirus is resistant to desiccation. J Infect Dis (1997) 1.30
Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets (2007) 1.26
Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine (2002) 1.25
Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J Gen Virol (2007) 1.25
Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res (2003) 1.24
HPV innate immunity. Front Biosci (2002) 1.21
Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine (2005) 1.19
Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res (2002) 1.15
Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes. J Virol (2001) 1.14
HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine (2005) 1.14
Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst (1997) 1.13
The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women. Am J Obstet Gynecol (1984) 1.11
Anal intraepithelial neoplasia and anal papillomavirus infection among homosexual males with group IV HIV disease. JAMA (1990) 1.11
Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther (2006) 1.08
Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol (2002) 1.08
Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine (2003) 1.07
Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int J Cancer (2006) 1.05
Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol (2003) 1.05
Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother (2004) 1.04
HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res (2007) 1.01
The biochemical and biological functions of human papillomavirus type 16 E5 protein. Arch Virol (2003) 1.00
Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol (2004) 0.99
Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. J Virol (2007) 0.97
Effects of 17beta-estradiol and progesterone on transcription of human papillomavirus 16 E6/E7 oncogenes in CaSki and SiHa cell lines. Int J Gynecol Cancer (2006) 0.97
T-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia. Clin Diagn Lab Immunol (1996) 0.96
Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia. J Gen Virol (1999) 0.94
A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. Gynecol Oncol (2004) 0.94
Activation of dendritic cells by human papillomavirus-like particles through TLR4 and NF-kappaB-mediated signalling, moderated by TGF-beta. Immunol Cell Biol (2005) 0.93
Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes. Arch Virol (2006) 0.93
Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. Vaccine (2005) 0.92
Role of cell-mediated immunity in spontaneous regression of plane warts. Int J Dermatol (1988) 0.92
Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems. J Med Virol (2003) 0.89
Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum (2002) 0.87
Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. Int J Cancer (2006) 0.86
Pluronic F127-based systemic vaccine delivery systems. Vaccine (2004) 0.85
Altered growth and viral gene expression in human papillomavirus type 16-containing cancer cell lines treated with progesterone. Cancer Invest (1999) 0.84
The role of exfoliative cytology and histopathology in screening and triage. Obstet Gynecol Clin North Am (1996) 0.84
Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody. Int J Cancer (2005) 0.84
Therapeutic cancer vaccines. Surg Oncol Clin N Am (2007) 0.81
Vaccination strategies for the treatment and prevention of cervical cancer. Curr Opin Oncol (2004) 0.81
Correlates of cervical mucosal antibodies to human papillomavirus 16: results from a case control study. Gynecol Oncol (2005) 0.81